Efficacy of donepezil in mild cognitive impairment
- 24 August 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (4) , 651-657
- https://doi.org/10.1212/01.wnl.0000134664.80320.92
Abstract
Objective: To evaluate the efficacy and safety of the acetylcholinesterase inhibitor donepezil in a placebo-controlled trial in patients with mild cognitive impairment (MCI). Methods: A total of 270 patients with MCI were enrolled in a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Patients were randomized to receive donepezil (n = 133; 5 mg/day for 42 days, followed by forced dose escalation to 10 mg/day) or placebo (n = 137). Primary efficacy measures were the New York University (NYU) Paragraph Delayed Recall test and the Alzheimer disease (AD) Cooperative Study Clinician’s Global Impression of Change for MCI (ADCS CGIC-MCI). Secondary efficacy measures included the modified AD Assessment Scale-cognitive subscale (ADAS-cog), the Patient Global Assessment (PGA), and additional neuropsychologic measures. Efficacy analyses were performed on intent-to-treat (ITT) and fully evaluable (FE) populations. Results: Primary efficacy measures of the NYU Paragraph Recall test and the ADCS CGIC-MCI did not show significant treatment effects in the ITT population. Some secondary measures showed effects favoring donepezil. More donepezil-treated patients showed improvements in ADAS-cog total scores, in tests of attention and psychomotor speed, and in PGA scores. More donepezil-treated than placebo-treated patients experienced adverse events, most of which were mild to moderate and transient. Conclusion: Although significant treatment effects were not seen in the primary efficacy measures, outcomes on secondary measures suggest promising directions for further evaluation of donepezil treatment in patients with MCI.Keywords
This publication has 31 references indexed in Scilit:
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of ChangeAlzheimer Disease & Associated Disorders, 1997
- Development of Cognitive Instruments for Use in Clinical Trials of Antidementia DrugsAlzheimer Disease & Associated Disorders, 1997
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Psychometric Differentiation of Mild Senile Dementia of the Alzheimer TypeArchives of Neurology, 1984
- Pathological verification of ischemic score in differentiation of dementiasAnnals of Neurology, 1980
- Physostigmine: Improvement of Long-Term Memory Processes in Normal HumansScience, 1978
- “Mini-mental state”Journal of Psychiatric Research, 1975
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960